AM-2201 is a potent synthetic cannabinoid (CB) with Ki values of 1.0 and 2.6 nM for the CB1 and CB2 receptors, respectively. AM-2201 acts as a potent but nonselective full agonist for the cannabinoid receptor. The physiological actions and metabolism of AM2201 have not been characterized.
|Source||Drug Alcohol Depend (2017). Figure 2. AM2201|
|Concentrations||0.1 – 0.3 mg/kg|
|Incubation Time||3 h|
|Results||THC and XLR-11 were the least potent of the cannabinoids, while CP55,940 was the most potent. JWH-018 and AM2201 had comparable potency at increasing BP and were intermediate between CP55,940 and THC.|
|Body Surface Area (m2)||0.007||0.025||0.15||0.05||0.02||0.5|
|Animal A (mg/kg) = Animal B (mg/kg) multiplied by||Animal B Km|
|Animal A Km|
For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.
Characteristics of the designer drug and synthetic cannabinoid receptor agonist AM-2201 regarding its chemistry and metabolism.
Hutter M, et al. J Mass Spectrom. 2013 Jul;48(7):885-94. PMID: 23832945.
First European case of convulsions related to analytically confirmed use of the synthetic cannabinoid receptor agonist AM-2201.
McQuade D, et al. Eur J Clin Pharmacol. 2013 Mar;69(3):373-6. PMID: 22936123.
|Related Cannabinoid Products|
LY2828360 is a novel potent, selective, and efficacious CB2 cannabinoid agonist.
BAY-59-3074 is a novel cannabinoid CB1/CB2 receptor partial agonist with Ki values of 48.3 and 45.5 nM at human CB1 and CB2 receptors, respectively.
(±)-SLV319 (Ibipinabant) is a potent and selective CB1 receptor antagonist (Ki = 7.8 nM). Exhibits 1000-fold selectivity for CB1 over CB2 receptors. Inhibits CP 55,940-induced hypotension and WIN 55,212-2-induced hypothermia in vivo.
GW842166X is a potent and highly selective agonist of cannabinoid receptor CB2 receptor with EC50 of 63 nM, shows no significant activity at CB1 receptor.
|WIN 55212-2 mesylate
WIN 55212-2 is a potent nanomolar affinity cannabinoid receptor agonist with Ki of 62.3 and 3.3 nM at the human cloned CB1 and CB2 receptors respectively.
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2017 AbMole BioScience. All Rights Reserved.